Integra LifeSciences (NASDAQ:IART – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.
A number of other research firms have also commented on IART. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Thursday, June 18th. BMO Capital Markets assumed coverage on Integra LifeSciences in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price objective on the stock. Citigroup reiterated a “neutral” rating and issued a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Truist Financial raised shares of Integra LifeSciences to a “hold” rating in a research report on Thursday. Finally, UBS Group assumed coverage on shares of Integra LifeSciences in a research report on Tuesday, July 28th. They set a “neutral” rating and a $19.00 target price for the company. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $18.43.
Read Our Latest Research Report on Integra LifeSciences
Integra LifeSciences Price Performance
Integra LifeSciences (NASDAQ:IART – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.08. The company had revenue of $418.76 million for the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, equities analysts expect that Integra LifeSciences will post 2.45 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in IART. Sequoia Financial Advisors LLC grew its holdings in Integra LifeSciences by 221.7% during the second quarter. Sequoia Financial Advisors LLC now owns 45,785 shares of the life sciences company’s stock worth $822,000 after buying an additional 31,552 shares in the last quarter. WINTON GROUP Ltd bought a new position in Integra LifeSciences during the 2nd quarter valued at $1,843,000. Integrated Wealth Concepts LLC purchased a new position in Integra LifeSciences during the 2nd quarter worth $84,000. Corient Private Wealth LP raised its holdings in shares of Integra LifeSciences by 66.9% in the second quarter. Corient Private Wealth LP now owns 22,749 shares of the life sciences company’s stock valued at $409,000 after purchasing an additional 9,120 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in shares of Integra LifeSciences by 12.4% during the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock valued at $26,241,000 after purchasing an additional 160,814 shares in the last quarter. 84.78% of the stock is owned by institutional investors.
Integra LifeSciences News Roundup
Here are the key news stories impacting Integra LifeSciences this week:
- Positive Sentiment: Integra expects to generate strong cash flow despite the disruption, while the proposed seven-year, $600 million Senior Secured Term Loan B could improve liquidity and refinance existing obligations. Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B
- Neutral Sentiment: Preliminary third-quarter adjusted EPS guidance is $0.55-$0.59, broadly in line with the $0.56 analyst consensus, suggesting the immediate-quarter impact may be manageable. Truist also upgraded the shares to a “Hold,” indicating a more balanced view rather than a bullish recommendation. Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
- Negative Sentiment: Integra reduced its 2026 revenue forecast to $1.634 billion-$1.654 billion from $1.654 billion-$1.695 billion. Full-year EPS guidance was lowered to $2.30-$2.40 from $2.40-$2.50, below the $2.46 consensus estimate. The cuts reflect production interruptions and millions of dollars in costs associated with the Cincinnati flooding. Integra LifeSciences Lowers Revenue and Earnings Outlook for 2026
- Negative Sentiment: The $600 million debt refinancing may support operations, but it also raises concerns about borrowing costs and leverage, particularly as profitability is being reduced by the flood-related disruption. The combination of lower guidance, facility uncertainty and additional secured debt explains why IART shares have decreased sharply and traded at unusually high volume. Integra Lowers FY26 Forecast Following Cincinnati Flood; Plans $600M Debt Refinance
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.
The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.
Featured Stories
- Five stocks we like better than Integra LifeSciences
- Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
- The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It
- McDonald’s Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers?
- MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning?
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
